These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7552714)

  • 21. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms.
    Sancho E; Declerck PJ; Price NC; Kelly SM; Booth NA
    Biochemistry; 1995 Jan; 34(3):1064-9. PubMed ID: 7827021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms.
    Hansen M; Busse MN; Andreasen PA
    Eur J Biochem; 2001 Dec; 268(23):6274-83. PubMed ID: 11733024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop.
    Debrock S; Declerck PJ
    Thromb Haemost; 1998 Mar; 79(3):597-601. PubMed ID: 9531048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
    Debrock S; Declerck PJ
    Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The reactive-center loop of active PAI-1 is folded close to the protein core and can be partially inserted.
    Hägglöf P; Bergström F; Wilczynska M; Johansson LB; Ny T
    J Mol Biol; 2004 Jan; 335(3):823-32. PubMed ID: 14687577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conformational studies of plasminogen activator inhibitor type 1 by fluorescence spectroscopy. Analysis of the reactive centre of inhibitory and substrate forms, and of their respective reactive-centre cleaved forms.
    Fa M; Bergström F; Karolin J; Johansson LB; Ny T
    Eur J Biochem; 2000 Jun; 267(12):3729-34. PubMed ID: 10848991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific interactions of serpins in their native forms attenuate their conformational transitions.
    Na YR; Im H
    Protein Sci; 2007 Aug; 16(8):1659-66. PubMed ID: 17600149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.
    Olson ST; Swanson R; Day D; Verhamme I; Kvassman J; Shore JD
    Biochemistry; 2001 Oct; 40(39):11742-56. PubMed ID: 11570875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1.
    Kvassman JO; Verhamme I; Shore JD
    Biochemistry; 1998 Nov; 37(44):15491-502. PubMed ID: 9799512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A.
    Kvassman JO; Lawrence DA; Shore JD
    J Biol Chem; 1995 Nov; 270(46):27942-7. PubMed ID: 7499270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
    Egelund R; Petersen TE; Andreasen PA
    Eur J Biochem; 2001 Feb; 268(3):673-85. PubMed ID: 11168406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies.
    Bijnens AP; Gils A; Knockaert I; Stassen JM; Declerck PJ
    J Biol Chem; 2000 Mar; 275(9):6375-80. PubMed ID: 10692438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solvent effects on activity and conformation of plasminogen activator inhibitor-1.
    Andreasen PA; Egelund R; Jensen S; Rodenburg KW
    Thromb Haemost; 1999 Mar; 81(3):407-14. PubMed ID: 10102470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F.
    Schousboe SL; Egelund R; Kirkegaard T; Preissner KT; Rodenburg KW; Andreasen PA
    Thromb Haemost; 2000 May; 83(5):742-51. PubMed ID: 10823273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
    Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
    Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymerization of plasminogen activator inhibitor-1.
    Zhou A; Faint R; Charlton P; Dafforn TR; Carrell RW; Lomas DA
    J Biol Chem; 2001 Mar; 276(12):9115-22. PubMed ID: 11102455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition.
    Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
    J Biol Chem; 1994 Nov; 269(44):27657-62. PubMed ID: 7961684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
    J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1.
    Na YR; Im H
    Protein Sci; 2005 Jan; 14(1):55-63. PubMed ID: 15576554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of plasminogen activator inhibitor 1 mutants containing the P13 to P10 region of ovalbumin or antithrombin III: evidence that the P13 residue contributes significantly to the active to substrate transition.
    Gils A; Vleugels N; Tobback K; Knockaert I; Declerck PJ
    Biochim Biophys Acta; 1998 Sep; 1387(1-2):291-7. PubMed ID: 9748634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.